Top

Cardiovascular Diabetology

Published in:

Open Access 01-12-2023 | Acute Coronary Syndrome | Research

Independent and joint associations between the triglyceride-glucose index and NT-proBNP with the risk of adverse cardiovascular events in patients with diabetes and acute coronary syndrome: a prospective cohort study

Authors: Man Wang, Li Zhou, Wen Su, Wenxi Dang, Hongwei Li, Hui Chen

Published in: Cardiovascular Diabetology | Issue 1/2023

Abstract

Background

Elevated triglyceride-glucose (TyG) index and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are independently associated with increased risk of major adverse cardio-cerebral events (MACCEs) in diabetic patients with the acute coronary syndrome (ACS), but have not been evaluated jointly. We sought to investigate the independent and joint association of the TyG index and NT-proBNP with MACCEs risk.

Methods

Data from 5046 patients with diabetes and ACS were recorded in the Cardiovascular Center Beijing Friendship Hospital Database Bank between 2013 and 2021, including measurements of fasting triglycerides, plasma glucose, and NT-proBNP. The TyG index was calculated as Ln (fasting triglycerides [mg/dL] × fasting plasma glucose [mg/dL]/2). Associations of the TyG index and NT-proBNP with MACCEs risk were assessed using flexible parametric survival models.

Results

During 13589.9 person-years of follow-up, 985 incident MACCEs of the 5046 patients (65.6 years of age and 62.0% men) were observed. Elevated TyG index (HR: 1.18; 95% CI 1.05‒1.32 per 1 unit increase) and NT-proBNP categories (HR: 1.95; 95% CI: 1.50‒2.54 for > 729 pg/ml compared to < 129 pg/ml) were independently associated with MACCEs risk in the fully adjusted model. According to the joint categories of the TyG index and NT-proBNP, patients with the TyG index > 9.336 and NT-proBNP > 729 pg/ml were at the highest risk of MACCEs (HR: 2.45; 95% CI 1.64‒3.65) than the ones with TyG index < 8.746 and NT-proBNP < 129 pg/ml. The test for interaction was not significant (P _interaction = 0.49). Incorporating these two biomarkers into the established clinical model, the Global Registry of Acute Coronary Events (GRACE) risk score, resulted in a significant improvement in risk stratification.

Conclusions

The TyG index and NT-proBNP were independently and jointly associated with the risk of MACCEs in patients with diabetes and ACS, suggesting that patients with both markers elevated should be aware of the higher risk in the future.

Available only for authorised users

Hao Y, Liu J, Liu J, Yang N, Smith SC Jr, Huo Y, Fonarow GC, Ge J, Taubert KA, Morgan L, et al. Sex Differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation. 2019;139(15):1776–85.PubMedCrossRef

Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43(4):585–91.PubMedCrossRef

Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298(7):765–75.PubMedCrossRef

Dotevall A, Hasdai D, Wallentin L, Battler A, Rosengren A. Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. Data from the euro heart survey ACS. Diabet Med. 2005;22(11):1542–50.PubMedCrossRef

Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC Jr, Ge J, Ma C, Han Y, Fonarow GC, et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the improving care for cardiovascular disease in China-Acute coronary syndrome project. Cardiovasc Diabetol. 2018;17(1):147.PubMedPubMedCentralCrossRef

Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32(8):1754–9.PubMedCrossRef

Sampath Kumar A, Maiya AG, Shastry BA, Vaishali K, Ravishankar N, Hazari A, Gundmi S, Jadhav R. Exercise and insulin resistance in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Phys Rehabil Med. 2019;62(2):98–103.PubMedCrossRef

Adeva-Andany MM, Martínez-Rodríguez J, González-Lucán M, Fernández-Fernández C, Castro-Quintela E. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metabol Syndr. 2019;13(2):1449–55.CrossRef

Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef

10.

Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavala MG, Hernández-González SO, Jacques-Camarena O, Rodríguez-Morán M. The product of triglycerides and glucose, a simple measure of insulin sensitivity Comparison with the Euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metabol. 2010;95(7):3347–51.CrossRef

11.

Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solis RC, Álvarez-Villalobos NA, González-González JG. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review. Int J Endocrinol. 2020;2020:4678526.PubMedPubMedCentralCrossRef

12.

Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, Tambascia MA, Saad MJ, Geloneze B. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–100.PubMedCrossRef

13.

Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum Á, Barbarash O, Chifamba J, Diaz ML, Gulec S, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy longevity. 2023;4(1):e23–33.PubMedCrossRef

14.

Tian X, Zuo Y, Chen S, Liu Q, Tao B, Wu S, Wang A. Triglyceride-glucose index is associated with the risk of myocardial infarction: an 11-year prospective study in the Kailuan cohort. Cardiovasc Diabetol. 2021;20(1):19.PubMedPubMedCentralCrossRef

15.

Zhang Y, Ding X, Hua B, Liu Q, Gao H, Chen H, Zhao XQ, Li W, Li H. Predictive effect of triglyceride-glucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China. Cardiovasc Diabetol. 2021;20(1):43.PubMedPubMedCentralCrossRef

16.

Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, Yang H, Ren LB, Qi W, Li WY, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.PubMedPubMedCentralCrossRef

17.

Bäsler I, Kuhn M, Müller W, Forssmann WG. Pituitary adenylate cyclase-activating polypeptide stimulates cardiodilatin/atrial natriuretic peptide (CDD/ANP-(99–126) secretion from cultured neonatal rat myocardiocytes. Eur J Pharmacol. 1995;291(3):335–42.PubMedCrossRef

18.

Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci. 2009;117(1):31–9.CrossRef

19.

Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, Maisel A, Peralta CA, Jacobs DR Jr. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the multi-ethnic study of atherosclerosis. Metabol Clin Experiment. 2014;63(4):475–83.CrossRef

20.

Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115(11):1345–53.PubMedCrossRef

21.

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46(4):660–6.PubMedCrossRef

22.

Krzesiński P, Piechota W, Piotrowicz K, Gielerak G, Woźniak-Kosek A. Association of estimated insulin resistance with N-terminal B-type natriuretic peptide concentration in men with metabolic syndrome. Cardiol Res Pract. 2019;2019:8571795.PubMedPubMedCentralCrossRef

23.

Wang JS, Lee CL, Lee WJ, Lee IT, Lin SY, Lee WL, Liang KW, Sheu WH. Statin treatment is associated with a negative correlation between NT-proBNP and insulin resistance in patients without history of heart failure. Clin Chim Acta. 2016;459:84–8.PubMedCrossRef

24.

Inoue Y, Kawai M, Minai K, Ogawa K, Nagoshi T, Ogawa T, Yoshimura M. The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure. Metabol Clin Experiment. 2016;65(3):38–47.CrossRef

25.

Idzerda NMA, Persson F, Pena MJ, Brenner BM, Brunel P, Chaturvedi N, McMurray JJ, Parving HH, de Zeeuw D, Heerspink HJL. N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes Obes Metab. 2018;20(12):2899–904.PubMedPubMedCentralCrossRef

26.

Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006;49(10):2256–62.PubMedCrossRef

27.

Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–54.PubMedCrossRef

28.

Chinese Society of Cardiology. Guideline for the diagnosis and management of ST-elevation myocardial infarction. Chinese J Cardiol. 2019;47(10):766–83.

29.

Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.PubMedCrossRef

30.

Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345–53.PubMedCrossRef

31.

Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.PubMedCrossRef

32.

Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265–90.CrossRef

33.

Hu Z-H, Peter Gale R, Zhang MJ. Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplant. 2020;55(3):538–43.PubMedCrossRef

34.

Le Borgne F, Combescure C, Gillaizeau F, Giral M, Chapal M, Giraudeau B, Foucher Y. Standardized and weighted time-dependent receiver operating characteristic curves to evaluate the intrinsic prognostic capacities of a marker by taking into account confounding factors. Stat Methods Med Res. 2018;27(11):3397–410.PubMedCrossRef

35.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9.PubMedCrossRef

36.

Haneuse S, VanderWeele TJ, Arterburn DJJ. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. JAMA. 2019;321(6):602–3.PubMedCrossRef

37.

Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, Shen H, Wang Z, Zhou Y, Liu X. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):31.PubMedPubMedCentralCrossRef

38.

Ciardullo S, Rea F, Cannistraci R, Muraca E, Perra S, Zerbini F, Mortara A, Perseghin G. NT-ProBNP and mortality across the spectrum of glucose tolerance in the general US population. Cardiovasc Diabetol. 2022;21(1):236.PubMedPubMedCentralCrossRef

39.

Sabbatinelli J, Giuliani A, Bonfigli AR, Ramini D, Matacchione G, Campolucci C, Ceka A, Tortato E, Rippo MR, Procopio AD, et al. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study. Cardiovasc Diabetol. 2022;21(1):180.PubMedPubMedCentralCrossRef

40.

Gerstein HC, Hess S, Claggett B, Dickstein K, Kober L, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Tardif JC, et al. Protein biomarkers and cardiovascular outcomes in people with type 2 diabetes and acute coronary syndrome: the ELIXA biomarker study. Diabetes Care. 2022;45(9):2152–5.PubMedCrossRef

41.

Ceriello A, Lalic N, Montanya E, Valensi P, Khunti K, Hummel M, Schnell O. NT-proBNP point-of-care measurement as a screening tool for heart failure and CVD risk in type 2 diabetes with hypertension. J Diabetes Complic. 2023;37(3):108410.CrossRef

42.

Stähli BE, Nozza A, Schrieks IC, Buse JB, Malmberg K, Mellbin L, Neal B, Nicholls SJ, Rydén L, Svensson A, et al. Homeostasis model assessment of insulin resistance and survival in patients with diabetes and acute coronary syndrome. J Clin Endocrinol Metab. 2018;103(7):2522–33.PubMedCrossRef

43.

Chang HR, Hsieh JC, Hsu BG, Wang LY, Chen MY, Wang JH. Inverse association of N-terminal pro-B-type natriuretic peptide with metabolic syndrome in patients with congestive heart failure. PLoS ONE. 2013;8(11):e79096.PubMedPubMedCentralCrossRef

44.

Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014;37(11):2899–908.PubMedCrossRef

45.

Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DA. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017;19(7):962–9.PubMedPubMedCentralCrossRef

46.

Witberg G, Ayers CR, Turer AT, Lev E, Kornowski R, de Lemos J, Neeland IJ. Relation of adiponectin to all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (from the Dallas Heart Study). Am J Cardiol. 2016;117(4):574–9.PubMedCrossRef

47.

Mukama T, Johnson T, Kaaks R, Katzke V. A case-cohort study of the association between adiponectin and mortality in EPIC-Heidelberg: NT-proBNP may explain the adiponectin paradox. Nutr Metab Cardiovasc Dis. 2023;33(4):853–63.PubMedCrossRef

48.

Chiu TH, Tsai HJ, Chiou HC, Wu PY, Huang JC, Chen SC. A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis. Int J Med Sci. 2021;18(4):1051–7.PubMedPubMedCentralCrossRef

49.

Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90(1):207–58.PubMedCrossRef

50.

Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2020;598(14):2977–93.PubMedCrossRef

51.

Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, Bao W. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018;362:k1497.PubMedPubMedCentralCrossRef

Title: Independent and joint associations between the triglyceride-glucose index and NT-proBNP with the risk of adverse cardiovascular events in patients with diabetes and acute coronary syndrome: a prospective cohort study
Authors: Man Wang
Li Zhou
Wen Su
Wenxi Dang
Hongwei Li
Hui Chen
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Acute Coronary Syndrome
Published in: Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-01890-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study

Triglyceride-glucose index and heart failure: a systematic review and meta-analysis

Correction: L-Arginine in diabetes: clinical and preclinical evidence

Predicting long-term prognosis after percutaneous coronary intervention in patients with new onset ST-elevation myocardial infarction: development and external validation of a nomogram model

Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2

Positive association of triglyceride-glucose index with new-onset hypertension among adults: a national cohort study in China

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials